Regeneron Pharmaceuticals to acquire 23andMe for $256 million post-bankruptcy, focusing on customer DNA data privacy amid concerns.
Read moreRecent study reveals the unique biology and evolutionary history of the elusive Australian marsupial mole.
Read more